ReithJD, GoldblumJR, LylesRH, WeissSW. Extragastrointes-tinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol.2000; 13: 577–585.
2.
RubinBP. Gastrointestinal stromal tumors: an update. Histopathology.2006; 48: 83–96.
3.
ErlandsonRA, KlimstraDS, WoodruffJM. Subclassification of gastrointestinal stromal tumors based on evaluation by electron microscopy and immunohistochemistry. Ultrastruct Pathol.1996; 20: 373–394.
4.
HjermstadBM, SobinLH, HelwigEB. Stromal tumors of the gastrointestinal tract. Myogenic or neurogenic? Am J Surg Pathol.1987; 11: 383–386.
MonihanJM, CarrNJ, SobinLH. CD 34 immunoexpression in stromal tumours of the gastrointestinal tract and in mesenteric fibromatoses. Histopathology.1994; 25: 469–473.
7.
HemmiA, KomiyamaA, OhnoS. Autonomic nerve tumour with skeinoid fibres: ultrastructure of skeinoid fibres examined by quick-freezing and deep-etching method. Virchows Arch.1999; 434: 267–276.
8.
MentzelT, KatenkampD. Gastrointestinal stromal tumour with skeinoid fibres and bidirectional immunohistochemical differentiation. Histopathology.1996; 29: 175–177.
9.
SakuraiS, HasegawaT, SakumaY. Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infiltrations: a subtype of GIST with mutations of platelet-derived growth factor receptor alpha gene. Hum Pathol.2004; 35: 1223–1230.
10.
SusterS, SoraceD, MoranCA. Gastrointestinal stromal tumors with prominent myxoid matrix. Clinicopathologic, immunohistochemical, and ultrastructural study of nine cases of a distinctive morphologic variant of myogenic stromal tumor. Am J Surg Pathol.1995; 19: 59–70.
11.
FerrerMD, LloretaJ, CorominasJM, RibaltaT, IglesiasM, SerranoS. Signet ring epithelioid stromal tumor of the small intestine. Ultrastruct Pathol.1999; 23: 45–50.
12.
RichmondJA, MountSL, SchwartzJE. Gastrointestinal stromal tumor of the stomach with rhabdoid phenotype: immunohistochemical, ultrastructural, and immunoelectron microscopic evaluation. Ultrastruct Pathol.2004; 28: 165–170.
13.
ShekTW, LukIS, LoongF, IpP, MaL. Inflammatory cell-rich gastrointestinal autonomic nerve tumor: an expansion of its histologic spectrum. Am J Surg Pathol.1996; 20: 325–331.
14.
CorlessCL, McGreeveyL, HaleyA, TownA, HeinrichMC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol.2002; 160: 1567–1572.
15.
HornickJL, FletcherCD. The significance of KIT (CD117) in gastrointestinal stromal tumors. Int J Surg Pathol.2004; 12: 93–98.
16.
MiettinenM, WangZF, LasotaJ. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol.2009; 33: 1401–1408.
17.
AnderssonJ, SjogrenH, Meis-KindblomJM, StenmanG, AmanP, KindblomLG. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol.2002; 160: 15–22.
18.
LuxML, RubinBP, BiaseTL. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol.2000; 156: 791–795.
RobinsonTL, SircarK, HewlettBR, ChorneykoK, RiddelRH, HuizingaJD. Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal. Am J Pathol.2000; 156: 1157–1163.
21.
VanderwindenJM, RumessenJJ, De LaetMH, VanderhaeghenJJ, SchiffmannSN. CD34+ cells in human intestine are fibroblasts adjacent to but distinct from interstitial cells of Cajal. Lab Invest.1999; 79: 59–65.
22.
EydenB, ChorneykoKA, ShanksJH, MenasceLP, BanerjeeSS. Contribution of electron microscopy to understanding cellular differentiation in mesenchymal tumors of the gastrointestinal tract: a study of 82 tumors. Ultrastruct Pathol.2002; 26: 269–285.
23.
MedeirosF, CorlessCL, DuensingA. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol.2004; 28: 889–894.
24.
LasotaJ, StachuraJ, MiettinenM. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest.2006; 86: 94–100.
25.
DaumO, GrossmanP, VanecekT, SimaR, MukensnablP, MichalM. Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors. Ann Diagn Pathol.2007; 11: 27–33.
EspinosaI, LeeC-H, KimMK. A novel monoclonal antibody against DOG1 in a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol.2008; 32: 210–218.
28.
WestRB, CorlessCL, ChenX. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol.2004; 165: 107–113.
29.
LieglB, HornickJL, CorlessCL, FletcherCD. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol.2009; 33: 437–446.
30.
BingZ, PashaTL, AcsG, ZhangPJ. Cytoplasmic overex-pression of WT-1 in gastrointestinal stromal tumor and other tissue tumors. Appl Immunohistochem Mol Morphol.2008; 16: 316–321.
YamaguchiU, HasegawaT, MasudaT. Differential diagnosis of gastrointestinal stromal tumor and other spindle cell tumors in the gastrointestinal tract based on immunohistochemical analysis. Virchows Arch.2004; 445: 142–150.
33.
YantissRK, SpiroIJ, ComptonCC, RosenbergAE. Gastrointestinal stromal tumor versus intra-abdominal fibromatosis of the bowel wall: a clinically important differential diagnosis. Am J Surg Pathol.2000; 24: 947–957.
34.
MontgomeryE, TorbensonMS, KaushalM, FisherC, AbrahamSC. Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am J Surg Pathol.2002; 26: 1296–1301.
35.
PetersonMR, PiaoZ, WeidnerN, YiES. Strong PDGFRA positivity is seen in GISTs but not in other intra-abdominal mesenchymal tumors. Immunohistochemical and mutational analysis. Appl Immunohistochem Mol Morphol.2006; 14: 390–396.
36.
RossiG, ValliR, BertoliniF. PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumors and other primary soft-tissue tumors of the gastrointestinal tract. Histopathology.2005; 46: 522–531.
MiettinenM, SobinLH, LasotaJ. Gastrointestinal stromal tumors of the stomach. A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol.2005; 29: 52–68.
39.
FullerCE, WilliamsGT. Gastrointestinal manifestations of type 1 neurofibromatosis (von Recklinghausen's disease). Histopathology.1991; 19: 1–11.
40.
SchaldenbrandJD, AppelmanHD. Solitary solid stromal gastrointestinal tumors in von Recklinghausen's disease with minimal smooth muscle differentiation. Hum Pathol.1984; 15: 229–232.
41.
TakazawaY, SakuraiS, SakumaY. Gastrointestinal stromal tumors of neurofibromatosis Type I (von Recklinghausen's disease). Am J Surg Pathol.2005; 29: 755–763.
42.
YantissRK, RosembergAE, SarranL, BesmerP, AntonescuCR. Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study. Mod Pathol.2005; 18: 475–484.
43.
CarneyJA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc.1999; 74: 543–552.
44.
DimentJ, TamboriniE, CasaliP, GronchiA, CarneyJA, ColecchiaM. Carney triad. Case report and molecular analysis of gastric tumor. Hum Pathol.2005; 36: 112–116.
45.
O'BrienP, KapustaL, DardickI, AxlerJ, GnidecA. Multiple familial gastrointestinal autonomic nerve tumors and small intestinal neuronal dysplasia. Am J Surg Pathol.1999; 23: 198–204.
46.
HirotaS, OkazakiT, KitamuraY, O'BrienP, KapustaL, DardickI. Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. Am J Surg Pathol.2000; 24: 326–327.
47.
AgaimyA, WunschPH, SobinLH, LasotaJ, MiettinenM. Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol.2006; 23: 120–127.
48.
KangDY, ParkCK, ChoiJS. Multiple gastrointestinal stromal tumors. Clinicopathologic and genetic analysis of 12 patients. Am J Surg Pathol.2007; 31: 224–232.
49.
AbrahamSC, KrasinskasAM, HofstetterWL, SwisherSG, WuT-T. “Seedling” mesenchymal tumors (gastrointestinal stromal tumors and leiomyomas) are common incidental tumors of the esophagogastric junction. Am J Surg Pathol.2007; 31: 1629–1635.
50.
KawanowaK, SakumaY, SakuraiS. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol.2006; 37: 1527–1535.
51.
RossiG, ValliR, BertoliniF. PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumors and other primary soft-tissue tumors of the gastrointestinal tract. Histopathology.2005; 46: 522–531.
52.
AgaimyA, DirnhoferS, WünschPH, TerraccianoLM, TornilloL, BihlMP. Multiple sporadic gastrointestinal stromal tumors (GISTs) of the proximal stomach are caused by different somatic KIT mutations suggesting a field effect. Am J Surg Pathol.2008; 32: 1553–1559.
53.
HallerF, SchultenHJ, ArmbrustT, LangerC, GunawanB, FüzesiL. Multicentric sporadic gastrointestinal stromal tumors (GISTs) of the stomach with distinct clonal origin: differential diagnosis to familial and syndromal GIST variants and peritoneal metastasis. Am J Surg Pathol.2007; 31: 933–937.
54.
AgaimyA, WünschPH, HofstaedterF. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol.2007; 31: 113–120.
55.
IrvingJA, LerwillMF, YoungRH. Gastrointestinal stromal tumors metastatic to the ovary. A report of five cases. Am J Surg Pathol.2005; 29: 920–926.
56.
Van der ZwanSM, DeMatteoRP. Gastrointestinal stromal tumor: 5 years later. Cancer.2005; 104: 1781–1788.
57.
De MatteoRP, HeinrichMC, El-RifaiWM, DemetriG. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol.2002; 33: 466–477.
58.
DemetriGD, von MehrenM, BlankeCD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med.2002; 347: 472–480.
59.
MechtersheimerG, EgererG, HenselM. Gastrointestinal stromal tumours and their response to treatment with the tyrosin kinase inhibitor imatinib. Virchows Arch.2004; 444: 108–118.
60.
HornickJL, FletcherCD. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol.2007; 38: 679–687.
61.
AntonescuCR. Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod Pathol.2008; 21: S31–S36.
Abdul-KaderI, Cameselle-TeijeiroJ, FortezaJ. Pathological changes related to imatinib treatment in a patient with a metastatic gastrointestinal stromal tumor. Histopathology.2005; 46: 470–472.
64.
PauwelsP, Debiec-RychterM, StulM, De WeverI, Van OosteromAT, SciotR. Changing phenotype of gastrointestinal stromal tumors under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology.2005; 47: 41–47.
65.
LieglB, HornickJL, AntonescuCR, CorlessCL, FletcherCD. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Am J Surg Pathol.2009; 33: 218–226.
AppelmanH, HelwigEB. Cellular leiomyomas of the stomach in 49 patients. Arch Pathol Lab Med.1977; 101: 373–377.
68.
RanchodM, KempsonRL. Smooth muscle tumors of the gastrointestinal tract and retroperitoneum. A pathologic analysis of 100 cases. Cancer.1977; 39: 255–262.
69.
WongNA, YoungR, MalcomsonRD. Prognostic indicators for gastrointestinal stromal tumors: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology.2003; 43: 118–126.
70.
FletcherCD, BermanJJ, CorlessC. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol.2000; 33: 459–465.
71.
FranquemontDW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol.1995; 103: 41–47.
72.
NakamuraN, YamamotoH, YaoT. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol.2005; 36: 828–837.
73.
EmoryTS, SobinLH, LukesL, LeeDH, O'LearyTJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol.1999; 23: 82–87.
74.
JoensuuH. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol.2008; 39: 1411–1419.
75.
MiettinenM, El-RifaiW, SobinLH, LasotaJ. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol.2002; 33: 478–483.
76.
FeakinsRM. The expression of p53 and bcl-2 in gastrointestinal stromal tumors is associated with anatomical site, and p53 expression is associated with grade and clinical outcome. Histopathology.2005; 46: 270–279.
77.
WeiYC, LiCF, YuSC. Ezrin overexpression in gastrointestinal stromal tumors: an independent adverse prognos-ticator associated with the non-gastric location. Mod Pathol.2009; 22: 1351–1360.
78.
LasotaJ, CorlessCL, HeinrichMC. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol.2008; 21: 476–484.
79.
LasotaJ, MiettinenM. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology.2008; 53: 245–266.
